Hong Kong Trade Distributors Stock News

CARsgen Therapeutics Holdings (SEHK:2171) has caught investor attention with an active streak of recent updates. In the past days, the company rolled out promising clinical trial results and approved a sizeable share buyback program. See our latest analysis for CARsgen Therapeutics Holdings. Despite a steep 12% decline in the past month, CARsgen’s share price has surged 76% year to date, reflecting renewed optimism driven by its clinical breakthroughs and buyback momentum. The company’s one...

Moon (SEHK:1723) remains unprofitable, with losses accelerating at a rapid pace of 74.3% per year over the last five years and no improvement in margins. The company’s shares are trading at a steep Price-to-Sales Ratio of 7.4x, far surpassing both its peer average of 0.1x and the broader Hong Kong electronic industry average of 0.5x. This implies that the current market price of HK$3.06 is well above the estimated fair value of HK$0.23. With no signs of profit growth, continued share...

Kinetic Development Group recently increased its stake in MC Mining to approximately 40.13% through completed share subscription tranches, with ambitions to reach a 51% holding as the Makhado Project in South Africa advances towards key infrastructure milestones by December 2025. This move highlights Kinetic’s intention to deepen its involvement in the mining sector and signals confidence in the development potential of the Makhado asset. We'll examine how Kinetic's push for majority...

In recent announcements by CSPC Pharmaceutical Group, the company received approval to begin clinical trials for its innovative siRNA drug SYH2061 targeting complement component C5, and its co-developed HER2-targeting antibody-drug conjugate JSKN003 was granted Breakthrough Therapy Designation in China for advanced colorectal cancer. These regulatory milestones highlight CSPC’s expanding capabilities in developing first-in-class treatments addressing significant unmet clinical needs within...

Chery Automobile (SEHK:9973) has been trading in a relatively narrow range, with its share price closing at HK$32.38. Over the past month, the stock edged up by 1%, reflecting investors’ cautious optimism. See our latest analysis for Chery Automobile. Momentum has been fairly muted for Chery Automobile, as this year’s modest 1.4% share price return suggests investors are still waiting to see if recent progress translates into stronger growth. After a flurry of updates earlier in the year, the...

BYD (SEHK:1211) just released new earnings showing sales have grown, but net income slipped compared to last year. This comes at a time when investors are questioning whether BYD can hold its lead in China’s crowded electric vehicle space. See our latest analysis for BYD. BYD's shares have been under pressure lately, with the stock sliding 11.7% over the past month as investors weigh up softening earnings and fierce competition from local EV makers. Despite this, the longer-term story remains...

Ascletis Pharma (SEHK:1672) has drawn attention this week by selecting ASC36, a once-monthly amylin receptor agonist, as its next clinical candidate for obesity treatment. The company intends to submit an IND for ASC36 to the U.S. FDA in 2026. See our latest analysis for Ascletis Pharma. Ascletis Pharma’s run of pipeline news, including the latest about ASC36, has helped fuel market momentum, even as recent weeks saw some volatility. After an incredible year-to-date share price return of...

Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like mazdutide and SINTBILO. See our latest analysis for Innovent Biologics. Innovent’s shares have been on a rollercoaster in recent weeks, but momentum is clearly building overall. The stock’s 1-year total shareholder return sits at an impressive 148%, even after some profit-taking since last month...

InnoCare Pharma recently announced two key milestones: the first patient was dosed in the clinical trial of their novel B7-H3 targeted antibody-drug conjugate (ADC) ICP-B794 in China, and positive phase I/II trial data for their next-generation pan-TRK inhibitor zurletrectinib in pediatric and adolescent patients were presented at the 2025 Congress of International Society of Paediatric Oncology. An important insight is that ICP-B794 targets a tumor-specific protein not yet addressed by any...

RemeGen (SEHK:9995) just grabbed the spotlight with new clinical data unveiled at the ESMO Congress and updated results for its myasthenia gravis therapy. The company also reported improved revenue and narrowing losses in its latest earnings report. See our latest analysis for RemeGen. These breakthroughs have put a fresh spotlight on RemeGen, and the market has taken notice. After a sharp sell-off in September, momentum has turned around in dramatic fashion. The stock’s 567.7% share price...

Shanghai Henlius Biotech (SEHK:2696) has entered a strategic partnership with Forlong Biotechnology to jointly develop next-generation cancer immunotherapies. This move brings together Henlius’s antibody expertise and Forlong’s engineered cytokine technologies, further expanding Henlius’s oncology pipeline. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s latest partnership news comes at a time when its stock has seen remarkable momentum, with the 1-year total...

China Hanking Holdings (SEHK:3788) has secured regulatory approval from Western Australia to commence dewatering at its Golden Pig gold mine. This approval unlocks the next phase of underground mining and could accelerate progress across the larger Cygnet gold project. See our latest analysis for China Hanking Holdings. China Hanking Holdings has been on a tear lately, with its 1-day share price return of 4.82% helping to erase some of the recent pullback. Despite some short-term volatility,...

Weichai Power Co., Ltd. reported earnings for the nine months ended September 30, 2025, posting sales of CNY 170.57 billion and net income of CNY 8.88 billion, both higher than the same period last year. The results showed an increase in both revenue and basic earnings per share from continuing operations, highlighting ongoing improvement in profitability and operational scale. With solid gains in sales and earnings, we'll examine how Weichai Power's consistent financial growth impacts its...

Li Ning (SEHK:2331) just held its Q3 2025 earnings call, drawing focused attention from investors and analysts. These quarterly updates provide a revealing look at the company’s financial health and management’s outlook for the months ahead. See our latest analysis for Li Ning. Li Ning’s Q3 earnings call appears to have been a catalyst for movement, with the share price rising 1.75% on the day but pulling back 7.05% over the past week. While short-term volatility remains, the company’s total...

Summit Therapeutics recently announced that results from multiple Phase III trials of ivonescimab, a first-in-class bispecific antibody developed by Akeso for cancer treatment, were presented at major medical meetings and published in The Lancet, with strong positive findings for non-small cell lung cancer (NSCLC) patients in China. This clinical progress has already contributed to regulatory approval, imminent U.S. regulatory submission, and inclusion in China's National Reimbursement Drug...

Ever wondered if Lenovo Group is truly a bargain, or if the market is missing something big? You are in the right place to dig into what is really driving value for this tech giant. Lenovo Group’s stock has been anything but flat, with a 16.0% year-to-date climb and an impressive 162.2% gain over the last five years, though it dipped -1.4% this week as the market recalibrated expectations. Global headlines have swirled around Lenovo's expansion in AI-powered devices and fresh investment in...

In late October 2025, Everest Medicines announced it had acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a bifunctional biologic for wet AMD, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and Southeast Asia through a collaboration with Visara, Inc. This marks Everest Medicines' entry into ophthalmology, adding a late-stage asset expected to be Phase-3-ready in 2026 and enhancing its portfolio diversification...

CITIC (SEHK:267) posted a net profit margin of 6.1%, just below last year’s 6.2%, while earnings grew 1.9% over the past year, beating its five-year average growth of 1.4% per year. Despite forecasts for revenue to fall by 6.1% per year over the next three years, the company’s earnings are projected to rise by 12.93% per year, edging out the broader Hong Kong market’s 12% growth forecast. With shares trading at HK$12.02, which is markedly below the estimated fair value, investors are likely...

COSCO SHIPPING Holdings Co., Ltd. recently reported unaudited earnings for the nine months ended September 30, 2025, showing sales of CNY167.60 billion and net income of CNY27.07 billion, both lower than the previous year. The decline in both revenue and net profit comes as the company continues to prioritize transparency and compliance with regulatory listing requirements in its financial reporting. We'll explore how the drop in net income and revenue shapes COSCO SHIPPING Holdings'...

MTR Corporation Limited recently announced a US$25 billion debt issuance programme with an application for listing on the Hong Kong Stock Exchange, available for 12 months from October 31. This substantial planned capital raise highlights MTR's intent to secure funding for future development, operational support, or potential refinancing amid changing market conditions. We'll assess how this significant debt programme may influence MTR's future financial flexibility and reshape its long-term...

The board of SmarTone Telecommunications Holdings Limited ( HKG:315 ) has announced that it will pay a dividend of...

PICC Property and Casualty Company Limited ( HKG:2328 ) has announced that it will pay a dividend of CN¥0.263 per share...

Investors who take an interest in Greentown Management Holdings Company Limited ( HKG:9979 ) should definitely note...

The Geotech Holdings Ltd. ( HKG:1707 ) share price has fared very poorly over the last month, falling by a substantial...